<DOC>
	<DOCNO>NCT01950741</DOCNO>
	<brief_summary>Effects VEGF Trap-Eye ( aflibercept ) treatment-naive polypoidal choroidal vasculopathy ( PCV ) evaluate .</brief_summary>
	<brief_title>Effect Intravitreal VEGF-Trap Eye Polypoidal Choroidal Vasculopathy</brief_title>
	<detailed_description>Efficacy VEGF Trap-Eye ( aflibercept , Eylea ) exudative age-related macular degeneration ( AMD ) demonstrate phase III VIEW study . Polypoidal choroidal vasculopathy ( PCV ) consider subtype exudative AMD , however reportedly different choroidal new vessel base histologic study . The aim study evaluate effect VEGF Trap-Eye treatment PCV , diagnose use indocyanine green ( ICG ) angiography . VEGF Trap-Eye inject intravitreally bimonthly 3 monthly load dose 12 month treatment-naive PCV patient . The efficacy evaluate preserve visual acuity improve angiographic feature 12 month .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<criteria>Submacular PCV diagnose use ICG angiography previous treatment ( branch vascular network without polypoidal dilation ICG angiography ) Presence sign recent activity PCV 1 . Visual acuity 20/40 20/320 2 . Active leakage fluorescein angiography 3 . Presence fluid OCT ( optical coherence tomography ) intraretinal , subretinal , subretinal pigment epithelial 1 . Extramacular PCV 2 . Subretinal hemorrhage retinal lesion block angiographic characteristic 50 % area PCV lesion . 3 . Previous treatment intravitreal injection ( antiVEGF , steroid agent ) 4 . Previous treatment photodynamic therapy 5 . Previous ocular surgery except cataract surgery 3 month 6 . Presence exudative AMD eye require antiVEGF treatment ( Intravitreal bevacizumab report affect eye . ) 7 . Presence ocular disease may affect visual acuity ( glaucoma , cataract opacity involve visual axis , etc ) 8 . Presence uncontrolled systemic disease ( diabetes mellitus , hypertension , ischemic heart disease , cerebral infarction , etc ) 9 . Patients understand conform study protocol . 10 . Patients refuse agree informed consent . 11 . Patients contraindication aflibercept Ocular periocular infection Active severe intraocular inflammation Known hypersensitivity aflibercept excipients</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>